Home > Gastroenterology > DDW 2022 > IBD > CD: Induction treatment with upadacitinib successful in clinical and endoscopic ratings

CD: Induction treatment with upadacitinib successful in clinical and endoscopic ratings

Presented By
Prof. Jean-Frederic Colombel, Mount Sinai Hospital, NY, USA
Conference
DDW 2022
Trial
Phase 3, U-EXCEED
Doi
https://doi.org/10.55788/13ea239a
Upadacitinib outperformed placebo in patients with moderate-to-severe Crohn’s disease (CD). Besides clinical remission and endoscopic response rates, steroid-free and endoscopic remissions were significantly higher on treatment with the JAK inhibitor. Upadacitinib showed promising results compared with placebo in the phase 2 CELEST trial (NCT02365649) and has thus advanced to double-blind, phase 3 testing [1]. Prof. Jean-Frederic Colombel (Mount Sinai Hospital, NY, USA) presented the results of U-EXCEED (NCT03345836), which investigated upadacitinib as induction therapy for patients with moderately-to-severely active CD who had a preceding inadequate response to biologics. The study randomised 495 patients 2:1 to receive either daily 45 mg upadacitinib or placebo ove...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on